165 related articles for article (PubMed ID: 25432025)
1. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Shao YX; Huang M; Cui W; Feng LJ; Wu Y; Cai Y; Li Z; Zhu X; Liu P; Wan Y; Ke H; Luo HB
J Med Chem; 2014 Dec; 57(24):10304-13. PubMed ID: 25432025
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.
Meng F; Hou J; Shao YX; Wu PY; Huang M; Zhu X; Cai Y; Li Z; Xu J; Liu P; Luo HB; Wan Y; Ke H
J Med Chem; 2012 Oct; 55(19):8549-58. PubMed ID: 22985069
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
[TBL] [Abstract][Full Text] [Related]
4. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
[TBL] [Abstract][Full Text] [Related]
6. Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.
Huang M; Shao Y; Hou J; Cui W; Liang B; Huang Y; Li Z; Wu Y; Zhu X; Liu P; Wan Y; Ke H; Luo HB
Mol Pharmacol; 2015 Nov; 88(5):836-45. PubMed ID: 26316540
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.
Wu Y; Wang Q; Jiang MY; Huang YY; Zhu Z; Han C; Tian YJ; Zhang B; Luo HB
J Med Chem; 2021 Jul; 64(13):9537-9549. PubMed ID: 34142552
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
9. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
Vardigan JD; Converso A; Hutson PH; Uslaner JM
J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
[TBL] [Abstract][Full Text] [Related]
10. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.
Zhang C; Zhou Q; Wu XN; Huang YD; Zhou J; Lai Z; Wu Y; Luo HB
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):260-270. PubMed ID: 29271265
[TBL] [Abstract][Full Text] [Related]
13. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
[TBL] [Abstract][Full Text] [Related]
14. Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
Wang H; Luo X; Ye M; Hou J; Robinson H; Ke H
J Med Chem; 2010 Feb; 53(4):1726-31. PubMed ID: 20121115
[TBL] [Abstract][Full Text] [Related]
15. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
[TBL] [Abstract][Full Text] [Related]
18. Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems.
Sivakumar D; Mudedla S; Jang S; Kim H; Park H; Choi Y; Oh J; Wu S
Biomolecules; 2021 May; 11(5):. PubMed ID: 34068780
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice.
da Silva FH; Pereira MN; Franco-Penteado CF; De Nucci G; Antunes E; Claudino MA
Int J Impot Res; 2013; 25(2):69-73. PubMed ID: 23034509
[TBL] [Abstract][Full Text] [Related]
20. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.
Huang Y; Wu XN; Zhou Q; Wu Y; Zheng D; Li Z; Guo L; Luo HB
J Med Chem; 2020 Dec; 63(24):15852-15863. PubMed ID: 33291877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
